燃石醫學(BNR.US)宣佈ADS比率變更
格隆匯4月27日丨2024年4月26日,專注於下一代測序(NGS)技術在精準腫瘤學領域的應用的公司燃石醫學(納斯達克股票代碼:BNR和倫敦證券交易所:BNR,該公司或Burning Rock)宣佈,它將把美國存托股(ADS)與A類普通股的比例從代表1股ADS的比例從代表1股ADS的比例更改為A類普通股的比例) A類普通股改為1股代表10股A類普通股的ADS("ADS比率變動")。ADS比率變更預計將於2024年5月15日左右(生效日期)生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.